Study Title
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Study Number
J2J-MC-JZLH/EMBER 4
Enrollment status
Open
Categories
Breast
Study Summary
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Study Coordinator(s)
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
Study Link
View Study DetailsAdditional Information
Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru